Clinical trials: Inflammatory Disease
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
- Trial name
- NCT07331272
- Testing
- LUCAR-G79D T cells
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Nanjing Legend Biotech Co.
Crohn Disease
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe…
- Trial name
- ICONIC-CD (NCT07196722)
- Testing
- Icotrokinra
- Where
- 395 sites in United States, Argentina and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin.
- Trial name
- CASCA (NCT06798012)
- Testing
- TAK-411
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Colitis, Ulcerative, Crohn Disease
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
The purpose of this study is to establish the incidence of sub-optimal response to anti-TNF therapy in UC and CD participants.
- Conditions
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- NCT03090139
- Testing
- Anti-TNF Therapy
- Where
- 76 sites in Argentina, China and 8 more
- Volunteers
- 1,731 people
- Sponsor
- Takeda
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Rectal Cancer, Colon Cancer
Perfusion Assessment in Laparoscopic Left Anterior Resection
The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic…
- Conditions
- Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp
- Trial name
- PILLAR II (NCT01560377)
- Testing
- PINPOINT Endoscopic Fluorescence Imaging System
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Ulcerative Colitis
Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis
The primary objective of the study was to compare the percentage of subjects in remission after 8 weeks of treatment with SPD476, 2.4 g/day once daily vs placebo and SPD476 4.8 g/day once daily versus placebo
- Trial name
- NCT00548574
- Testing
- SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine, Mesalazine
- Where
- Belgium
- Volunteers
- 343 people
- Sponsor
- Shire
Ulcerative Colitis
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
The purpose of this study is to determine the safety and tolerability of the MDX-1100 regimen in subjects with active Ulcerative colitis(UC) and determine the response rate at day 57 in patients administered MDX-1100.
- Trial name
- MDX1100-06 (NCT00656890)
- Testing
- sterile saline for injection, MDX-1100
- Where
- 44 sites in United States, Canada and 6 more
- Volunteers
- 110 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Crohn's Disease
Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study.
- Trial name
- NCT03870334
- Testing
- BT-11 880 mg
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NImmune Biopharma
Chronic Inflammatory Demyelinating Polyneuropathy
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP.
- Trial name
- NCT05581199
- Testing
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 94 people
- Sponsor
- Immunovant Sciences GmbH
Ulcerative Colitis
A Study of Abatacept in Patients With Active Ulcerative Colitis
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00410410
- Testing
- abatacept (ABA), abatacept
- Where
- 143 sites in United States, Australia and 17 more
- Volunteers
- 591 people
- Sponsor
- Bristol-Myers Squibb
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
Acute Kidney Injury, Septic Shock
Targeting Abdominal Perfusion Pressure in Septic Shock
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
- Conditions
- Acute Kidney Injury, Septic Shock, Resuscitations
- Trial name
- MAP-APP (NCT03582046)
- Testing
- Abdominal Perfusion Pressure (APP), Mean Arterial Pressure (MAP)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Potrero Medical
Crohn's Disease
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
The primary objective of this study is to establish the safety and tolerability of multiple ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily for 5 days per week over 2 weeks in…
- Trial name
- NCT05028946
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Ulcerative Colitis
Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis
The study is designed to investigate efficacy and safety of CU104 in patients with moderate to severe ulcerative colitis.
- Trial name
- UC (NCT05907330)
- Testing
- CU104
- Volunteers
- 45 people
- Sponsor
- Curacle Co., Ltd.
Covid19, Sepsis
Feasibility Study of Hematology Parameters in COVID-19 Disease
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or…
- Conditions
- Covid19, Sepsis, Adults, Emergency Department
- Trial name
- NCT04816630
- Testing
- CBC-Diff Monocyte Volume Width Distribution
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beckman Coulter, Inc.
Chronic Inflammatory Disorder, Arthritis, Rheumatoid
A Relative Bioavailability and Food Effect Study of New Formulations
The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food.
- Trial name
- NCT01398475
- Testing
- LY3009104
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part…
- Trial name
- NCT04458805
- Testing
- NX-13 250 mg
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Landos Biopharma Inc.
Crohn Disease, Colitis, Ulcerative
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
- Conditions
- Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
- Trial name
- UNITED (NCT05092269)
- Testing
- Ustekinumab
- Where
- 48 sites in United States, Argentina and 11 more
- Volunteers
- 159 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.